سعر فيلوبريس 2.5 / 2.5 مجم 21 قرص 2022

Felodipine 2.5 mg + ramipril 2.5 mg film-coated tablets (Liptis), 21 tablets.

• Essential hypertension in patients whose blood pressure is not adequately controlled on felodipine or ramipril alone.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland

• Felodipine component: peripheral oedema (very common), headache and flushing (common), dizziness, palpitations, hypotension, GI upset, rash; ramipril component: ACE-inhibitor effects such as cough, hypotension, hyperkalaemia, angioedema and blood dyscrasias.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to felodipine/dihydropyridines, ramipril/ACE inhibitors or excipients; history of angioedema; use with sacubitril/valsartan; unstable haemodynamic conditions (shock, untreated heart failure, acute MI, unstable angina, stroke); significant valvular or dynamic outflow obstruction; AV block II-III; severe hepatic impairment; CrCl <20 ml/min or dialysis; pregnancy; lactation; with aliskiren in diabetes or GFR <60.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Angioedema (including intestinal) requires immediate discontinuation; dual RAAS blockade (ACE inhibitor + ARB or aliskiren) not recommended; monitor renal function, potassium (hyperkalaemia risk) and sodium; agranulocytosis/neutropenia possible — check white cell counts; risk of severe hypotension in renovascular hypertension or volume depletion.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Sacubitril/valsartanContraindicated (angioedema risk); do not start sacubitril/valsartan until 36 hours after the last dose.Health Products Regulatory Authority (HPRA), Ireland
• Potassium salts, potassium-sparing diuretics, heparin, trimethoprim, ciclosporin, tacrolimusIncreased risk of hyperkalaemia; monitor serum potassium.Health Products Regulatory Authority (HPRA), Ireland
• NSAIDs; increased dietary saltMay reduce the antihypertensive effect; close blood-pressure monitoring recommended.Health Products Regulatory Authority (HPRA), Ireland

• Contraindicated in pregnancy: ACE-inhibitor exposure in the second and third trimesters causes foetotoxicity (reduced renal function, oligohydramnios, delayed skull ossification) and neonatal toxicity; stop immediately when pregnancy is diagnosed.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Women must not breast-feed during treatment (felodipine is excreted in human milk; ramipril excretion unknown).International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Felodipine: Vasoselective long-acting dihydropyridine that blocks L-type calcium channels in arteriolar smooth muscle, reducing peripheral vascular resistance and blood pressure.
• Ramipril: Prodrug hydrolysed to ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone secretion.